Journal of Viral Hepatitis

Article	Citations
Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy	55
Clinical characteristics in patients with SARS‐CoV‐2/HBV co‐infection	48
Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta	46
Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis	41
Hepatitis E virus genome detection in commercial pork livers and pork meat products in Germany	37
The impact of SVR from direct‐acting antiviral‐ and interferon‐based treatments for HCV on hepatocellular carcinoma risk	34
Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study	34
COVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later	31
Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study	31
SARS‐CoV‐2 infection in patients with a normal or abnormal liver	28
Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone	27
The case for simplifying and using absolute targets for viral hepatitis elimination goals	27
Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta‐analysis	26
Altered faecal microbiota on the expression of Th cells responses in the exacerbation of patients with hepatitis E infection	26
Loss to follow‐up in the hepatitis C care cascade: A substantial problem but opportunity for micro‐elimination	26
Unexpected long‐lasting anti‐HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?	25
Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study	25
A same day ‘test and treat’ model for chronic HCV and HBV infection: Results from two community‐based pilot studies in Egypt	24
Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis	22
Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysis	22
Clinical effects of NTCP‐inhibitor myrcludex B	22
Randomized clinical trials towards a single‐visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG‐101 in chronic hepatitis C patients and long‐acting injectable GSK2878175 in healthy p	21
Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry	21
Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B	20
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study	20

Risk of hepatocellular carcinoma in hepatitis B and D virus co‐infected patients: A systematic review and meta‐analysis of longitudinal studies	20
Hepatitis delta virus propagation enabled by hepatitis C virus—Scientifically intriguing, but is it relevant to clinical practice?	20
Mucosal‐associated invariant T‐cells are severely reduced and exhausted in humans with chronic HBV infection	20
Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium	20
Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B	19
Network‐based recruitment of people who inject drugs for hepatitis C testing and linkage to care	18
Treatment for chronic hepatitis E virus infection: A systematic review and meta‐analysis	18
Hepatitis C treatment in a co‐located mental health and alcohol and drug service using a nurse‐led model of care	18
HCV micro‐elimination in two prisons in Milan, Italy: A model of care	18
The impact of the first, second and third waves of covid‐19 on hepatitis B and C testing in Ontario, Canada	17
Disease burden of viral hepatitis A, B, C and E: A systematic analysis	17
Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B	17
Transmission of hepatitis C virus in HIV‐positive and PrEP‐using MSM in England	16
Novel hepatitis B virus surface antigen mutations associated with occult genotype B hepatitis B virus infection affect HBsAg detection	16
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real‐World Study	16
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy	16
Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA	16
Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019	15
What drives the dynamics of HBV RNA during treatment?	15
The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta‐analysis	15
Innovative procedures for micro‐elimination of HCV infection in persons who use drugs	14
Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany	14
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B	14
The effects of hepatitis B virus infection on natural and IVF pregnancy: A meta‐analysis study	14
Baseline HBV‐DNA load plus AST/ALT ratio predicts prognosis of HBV‐related hepatocellular carcinoma after hepatectomy: A multicentre study	13
Patient and provider‐level barriers to hepatitis C screening and linkage to care: A mixed‐methods evaluation	13
Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response	13
Global prevalence of occult hepatitis B: A systematic review and meta‐analysis	13
Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C‐infected patients (ANRS CO22 Hepather cohort)	12
HBcrAg and pg RNA and the therapeutic effect in HBeAg‐positive patients receiving anti‐viral therapy, baseline serum HBV‐RNA is a powerful predictor of response	12
Acute Delta Hepatitis in Italy spanning three decades (1991–2019): Evidence for the effectiveness of the hepatitis B vaccination campaign	12
Persistent Hepatitis E virus infection across England and Wales 2009‐2017: Demography, virology and outcomes	12
Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy	12
Development and validation of a hepatitis B‐specific health‐related quality‐of‐life instrument: CLDQ‐HBV	12
Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist	12
The impact of DAA‐mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort	11
Detection, stratification and treatment of hepatitis C–positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London	11
Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatiti	11
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort	11
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations	11
Association between viral hepatitis infection and Parkinson's disease: A population‐based prospective study	11
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phas	11
Mean HBsAg decline at week 24 of PEG‐IFN‐based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials	11
The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients	11
Impact of maternal infection with hepatitis B virus on pregnancy complications and neonatal outcomes for women undergoing assisted reproductive technology treatment: A population‐based study	11
Prevalence of hepatitis E infection among adults with concurrent chronic liver disease	11
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C	11
Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study	10
First evidence for continuous circulation of hepatitis A virus subgenotype IIA in Central Africa	10
Determinants of stigma among patients with hepatitis C virus infection	10

Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus‐co‐infected patients in Myanmar	10
Non‐invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)‐associated liver disease and sustained virologic response (SVR): 3 year	10
The role of caesarean section and nonbreastfeeding in preventing mother‐to‐child transmission of hepatitis B virus in HBsAg‐and HBeAg‐positive mothers: results from a prospective cohort study and a me	10
Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection	10
Chronic hepatitis D—What is changing?	10
Anti‐HBc‐nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults	10
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap‐based combination therapy	10
The impact of point‐of‐care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study	10
Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population‐based cohort studies	10
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia	10
The role of gut microbiota in hepatitis B disease progression and treatment	9
High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre‐exposure prophylaxis	9
The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals	9
Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia	9
Comparison of 48‐week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta‐analysis	9
Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland	9
Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance	9
Characterization of hepatitis E virus natural infection in farmed rabbits	9
Prevalence and short‐term outcome of acute kidney injury in patients with acute‐on‐chronic liver failure: A meta‐analysis	9
Prevalence and clinical features of patients with concurrent HBsAg and anti‐HBs: Evaluation of the hepatitis B research network cohort	9
The impact of direct‐acting antivirals on hepatitis C viraemia among people who inject drugs in England; real‐world data 2011–2018	9
High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study	9
Role of peer support in a hepatitis C elimination programme	8
Point‐of‐care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination	8
Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival	8
Cost‐effectiveness of screening and treatment using direct‐acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan	8
Viral hepatitis C pandemic: Challenges and threats to its elimination	8
Real‐world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan	8
Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland	8
Validation of hepatitis C virus RNA detection using capillary blood by finger prick (GenXpert system)—Hepatitis C fingerprick study	8
HBV variants are common in the ‘immune‐tolerant’ phase of chronic hepatitis B	8
Analytical validation of hepatitis B core‐related antigen (HBcrAg) using dried blood spots (DBS)	8
Rates of perfect self‐reported adherence to direct‐acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study	8
Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B	8
Intrahepatic T helper 17 cells recruited by hepatitis B virus X antigen‐activated hepatic stellate cells exacerbate the progression of chronic hepatitis B virus infection	8
Prognosis of hepatitis E infection in patients with chronic liver disease: A meta‐analysis	8
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review	8
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir	7
Hepatitis E‐Associated Hospitalizations in the United States: 2010–2015 and 2015–2017	7
Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir	7
Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus–related decompensated cirrhosis	7
Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta‐analysis	7
Telemedicine HCV treatment in department of corrections results in high SVR in era of direct‐acting antivirals	7
Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment	7
No evidence of sexual transmission of HEV among individuals using HIV pre‐exposure prophylaxis	7
Evaluating the prevalence of Hepatitis E virus infection in a large cohort of European blood donors, 2015–2018	7
Epidemiology estimates of hepatitis D in individuals co‐infected with human immunodeficiency virus and hepatitis B virus, 2002–2018: A systematic review and meta‐analysis	7
Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non‐cirrhotic HBeAg‐positive chronic hepatitis B	7
Hepatitis C testing and treatment uptake among young people who use opioids in New York City: A cross‐sectional study	7
The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection	7
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA	7
Identification of hepatitis B virus aetiologic antigens, HBx and Pre‐S2, in diffuse large B‐cell lymphoma	7
Resistance‐associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure	7
Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy	7
Beneficial effects of DAAs on cardiac function and structure in hepatitis C patients with low‐moderate liver fibrosis	7
Real‐world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype	7
A multi‐centre study of trends in hepatitis B virus‐related hepatocellular carcinoma risk over time during long‐term entecavir therapy	7
How do people in prison feel about opt‐out hepatitis C virus testing?	7
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics	7
Maternal chronic hepatitis B virus infection and the risk of preterm birth: A retrospective cohort analysis in Chinese women	7
Efficacy of an accelerated double‐dose hepatitis B vaccine regimen in patients with cirrhosis	7
The genetic polymorphism down‐regulating HLA‐DRB1 enhancer activity facilitates HBV persistence, evolution and hepatocarcinogenesis in the Chinese Han population	7
Progress towards the elimination of hepatitis B in children in Colombia: A novel two‐phase study approach	7
Risk of drug‐induced liver injury in chronic hepatitis B and tuberculosis co‐infection: A systematic review and meta‐analysis	7
Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study	7
The 48‐week safety and therapeutic effects of tenofovir alafenamide in hbv‐related acute‐on‐chronic liver failure: A prospective cohort study	7
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐19	6
Real‐world study on HBsAg loss of combination therapy in HBeAg‐negative chronic hepatitis B patients	6
HIV influences clustering and intracellular replication of hepatitis C virus	6
High body mass index hinders fibrosis improvement in patients receiving long‐term tenofovir therapy in hepatitis B virus‐related cirrhosis	6
Meta‐analysis: Association between hepatitis B virus preS mutation and hepatocellular carcinoma risk	6
Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma	6
VirA+EmiC project: Evaluating real‐world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department	6
Altered balance between collagen formation and degradation after successful direct‐acting antiviral therapy of chronic hepatitis C	6
No influence of hepatic steatosis on the 3‐year outcomes of patients with quiescent chronic hepatitis B	6
Provider‐related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis	6
Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort	6
Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy without antiviral prophylaxis	6
Effects of on‐treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection	6
Hepatitis B virus–induced hepatocarcinogenesis: A virological and oncological perspective	6

Hepatitis C related cognitive impairment: Impact of viral and host factors and response to therapy	6
Distinct Hepatitis B and HIV co‐infected populations in Canada	6
Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study	6
Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection	6
Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya	6
Inhibition of hepatitis E virus replication by zinc‐finger antiviral Protein synergizes with IFN‐β	6
Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia	6
Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non‐target sites, for DAA‐based treatment and retreatment outcome	6
Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment	6
Temporal and geographic spreading of hepatitis B virus genotype A (HBV‐A) in Brazil and the Americas	6
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation	6
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals	6
Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication	6
Internet‐guided HCV‐RNA testing: A promising tool to achieve hepatitis C micro‐elimination among men who have sex with men	6
Insight into an acute hepatitis A outbreak in Indiana	6
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus‐coinfected patients receiving sofosbuvir‐based direct‐acting antivirals and antiretroviral thera	6
Hepatitis B surface antibody titres and hepatitis B reactivation with direct‐acting antiviral therapy for hepatitis C	6
RETRACTED: Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV‐DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	6
Characteristics of regulatory T‐cell function in patients with chronic hepatitis B and C coinfection	6
Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or ‘re‐diagnose’ infections is effective in Australia	6
Patient‐reported outcomes of the Treatment and Prevention Study: A real‐world community‐based trial of direct‐acting antivirals for hepatitis C among people who inject drugs	6
Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study	6